Cargando…

PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level

Programmed cell death-1 (PD-1) -targeted immunotherapy has become a promising treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). Clinical responses to checkpoint inhibition therapy in NSCLC have been associated with programmed death-1 ligand 1 (PD-L1) expression. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Lianjing, Wang, Xinyue, Li, Shouying, Zhi, Qiongjie, Wang, Yuqian, Wang, Liuchun, Li, Kai, Jiang, Richeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665041/ https://www.ncbi.nlm.nih.gov/pubmed/29158797 http://dx.doi.org/10.7150/jca.21118

Ejemplares similares

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements
por: Li, Shouying, et al.
Publicado: (2019)

Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer
por: Wang, Xinyue, et al.
Publicado: (2019)

Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma
por: Zhi, Qiongjie, et al.
Publicado: (2016)

Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2
por: Yin, Lei, et al.
Publicado: (2010)

Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma
por: Catanzaro, Joseph M., et al.
Publicado: (2011)

Salivary Scca1, Scca2 and Trop2 in Oral Cancer Patients—A Cross-Sectional Pilot Study
por: Karmelić, Ivana, et al.
Publicado: (2022)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

Metabolomics and lipid profile analysis of Coccomyxa melkonianii SCCA 048
por: Fais, Giacomo, et al.
Publicado: (2021)

Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
por: Jiang, Richeng, et al.
Publicado: (2016)

Exploring Brain Structural and Functional Biomarkers in Schizophrenia via Brain-Network-Constrained Multi-View SCCA
por: Song, Peilun, et al.
Publicado: (2022)

Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer
por: Qu, Tao, et al.
Publicado: (2019)

Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty
por: Du, Lei, et al.
Publicado: (2017)

Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma
por: Zheng, Xin, et al.
Publicado: (2014)

Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC
por: Trerotoli, Paolo, et al.
Publicado: (2009)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation
por: Wang, Songyan, et al.
Publicado: (2022)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases
por: Izuhara, Kenji, et al.
Publicado: (2018)

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study
por: Liu, Zhujun, et al.
Publicado: (2018)

The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review
por: Zhou, Ziqi, et al.
Publicado: (2017)

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production
por: Chen, Liyun, et al.
Publicado: (2023)

Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett’s carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy
por: Fassan, Matteo, et al.
Publicado: (2016)

Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions
por: Han, Cuina, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

15-PGJ(2), but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells
por: Nikitakis, N G, et al.
Publicado: (2002)

AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease
por: Beale, Gary, et al.
Publicado: (2008)

Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer
por: Ran, Chao, et al.
Publicado: (2021)

Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Jiang, Richeng, et al.
Publicado: (2016)

Construction and analysis of a novel ferroptosis‐related gene signature predicting prognosis in lung adenocarcinoma
por: Zhou, Jing, et al.
Publicado: (2021)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

A sandwich SERS immunoassay platform based on a single-layer Au–Ag nanobox array substrate for simultaneous detection of SCCA and survivin in serum of patients with cervical lesions
por: Liu, Yifan, et al.
Publicado: (2021)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
por: Yi, Ling, et al.
Publicado: (2023)

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
por: Jiang, Li, et al.
Publicado: (2019)

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
por: Li, Chuling, et al.
Publicado: (2019)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
por: Norum, Jan, et al.
Publicado: (2018)

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
por: Zhang, Linlin, et al.
Publicado: (2023)

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
por: Zhao, Honghui, et al.
Publicado: (2022)

Long-Term Recurrence of Completely Resected NSCLC
por: Masago, Katsuhiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uc5u49736aid1lr7qsq3gre87c